The Patent Finder

Fasl Expression and Fasr Gene Knockout to Protect Therapeutic Cells from Allogeneic Rejection and Activation-Induced Cell Death

Allogene Therapeutics, Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresPatent lifetimeUsedRemainingConfidence
US 12,577,290Fasl Expression and Fasr Gene Knockout to Protect Therapeutic Cells from Allogeneic Rejection and Activation-Induced Cell Death
In force
 · High confidence
UsedRemaining
Allogene Therapeutics, Inc.In forceHigh confidence
Application 19/543,807Fasl Expression and Fasr Gene Knockout to Protect Therapeutic Cells from Allogeneic Rejection and Activation-Induced Cell Death
Pending
Not granted
Allogene Therapeutics, Inc.PendingNot granted
2 of 2 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by Allogene Therapeutics, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited